OpenAlex
PricingAboutJobs
Log inGet started
Work

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

HTML

Year: 2015
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Allergy and Clinical Immunology
DOI: 10.1016/j.jaci.2015.01.018
Authors: James G. Krueger, Laura K. Ferris, Alan Menter, Frank Wagner, Alexander White, Sudha Visvanathan, Bojan Lalovic, Stella Aslanyan, Elaine E.L. Wang, David Hall, Alan Solinger, Steven Padula, Paul Scholl
Institutions: Rockefeller University, UPMC Health System, University of Pittsburgh Medical Center, Stiftung Charité, Charité – Universitätsmedizin Berlin, Clinical Research Puerto Rico, Boehringer Ingelheim (United States), Boehringer Ingelheim (Germany)
Language: English

Topic: Psoriasis: Treatment and Pathogenesis
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: anti-IL-23 monoclonal antibody, plaque psoriasis, moderate-to-severe psoriasis, first-in-human safety, pharmacokinetics, biomarkers, Psoriasis Area and Severity Index
SDG: Good health and well-being

Open Access status: closed

Funders: Eli Lilly and Company, Pfizer, Boehringer Ingelheim
OpenAlex ID: W2003687140
FWCI: 17.05
Cites: 27
Cited by: 273
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms